Evolus posts quarterly profit on strong sales of cosmetic injection
Evolus reported a quarterly profit amid strong demand for Jeuveau. Jeuveau's performance is positively impacting Evolus's financial outlook.
View signal analysisCompany intelligence
EOLS
Evolus, Inc. · NASDAQ · Healthcare
Price$8.00+0.13% · +$0.01
Market cap526.84MEquity value
P / E-25.3Trailing ratio
Volume624.36KLatest session
Market data
TradingViewEOLS price chart
Related signals
1 min delayedLatest EOLS price-moving signals
Browse public EOLS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
US FDA approves Evolus' anti-wrinkle gels
Evolus has received FDA approval for two new anti-wrinkle injectables, enhancing their portfolio. This approval may lead to increased market share and revenue for Evolus.
View signal analysisEvolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
- Evolus reported a quarterly loss of $0.13 per share, missing estimates. - Revenue for the quarter ended March 2024 was $59.33 million. - Company's stock has outperformed S&P 500, with an increase of 27.2% this year. - Estimate revisions trend for Evolus is currently favorable. - The Zacks Rank for Evolus is #2 (Buy), expecting to outperform the market. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysisResearch